Literature DB >> 23007604

Involvement of serotonin-mediated neurotransmission in the dorsal periaqueductal gray matter on cannabidiol chronic effects in panic-like responses in rats.

Alline Cristina Campos1, Vanessa de Paula Soares, Milene C Carvalho, Frederico Rogerio Ferreira, Maria Adrielle Vicente, Marcus Lira Brandão, Antonio Waldo Zuardi, Hélio Zangrossi, Francisco Silveira Guimarães.   

Abstract

RATIONALE: Cannabidiol (CBD) is a non-psychotomimetic constituent of Cannabis sativa plant that promotes antianxiety and anti-panic effects in animal models after acute systemic or intra-dorsal periaqueductal gray (DPAG) administration. However, the effects of CBD repeated administration, and the possible mechanisms involved, in animal models of anxiety- and panic-related responses remain poorly understood.
OBJECTIVE: The present study evaluates the role of the serotonergic neurotransmission within the DPAG in the modulation of escape responses of rats chronically treated with CBD.
METHODS: Male Wistar rats received acute or repeated (5 mg/Kg/daily/21 days) administration of CBD and were submitted to the elevated T-maze (ETM). We also investigated if CBD effects on the ETM depend on facilitation of 5-HT1A-mediated neurotransmission in the DPAG. To this latter aim, we verified if these effects would be prevented by intra-DPAG injection of the 5-HT1A receptor antagonist WAY100635 (0.37 nmol/0.2 μL). Also, we verified, by in vivo microdialysis, if CBD chronic treatment increases serotonin (5-HT) release and, by quantitative polymerase chain reaction, if there are changes in 5HT-1A or 5HT-2C mRNA expression in DPAG.
RESULTS: The results showed that repeated but not acute peripheral administration of CBD decreases escape responses in the ETM, suggesting a panicolytic effect. This treatment did not change 5HT-1A or 5-HT-2C receptor mRNA expression nor modify serotonin extracellular concentrations in the DPAG. CBD effects were prevented by DPAG injection of the 5-HT1A receptor antagonist.
CONCLUSIONS: Together, these findings suggest that repeated treatment with CBD induces anti-panic effects by acting on 5-HT1A receptors in DPAG.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23007604     DOI: 10.1007/s00213-012-2878-7

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  50 in total

1.  Intra-dorsal periaqueductal gray administration of cannabidiol blocks panic-like response by activating 5-HT1A receptors.

Authors:  Vanessa de Paula Soares; Alline Cristina Campos; Valquíria Camin de Bortoli; Hélio Zangrossi; Francisco Silveira Guimarães; Antonio Waldo Zuardi
Journal:  Behav Brain Res       Date:  2010-05-08       Impact factor: 3.332

2.  Anxiolytic-like effect of cannabidiol in the rat Vogel conflict test.

Authors:  Fabrício A Moreira; Daniele C Aguiar; Francisco S Guimarães
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2006-07-31       Impact factor: 5.067

3.  WAY100635 prevents the changes induced by fluoxetine upon the 5-HT1A receptor functionality.

Authors:  Elena Castro; Alvaro Díaz; Antonio Rodriguez-Gaztelumendi; Elena Del Olmo; Angel Pazos
Journal:  Neuropharmacology       Date:  2008-09-17       Impact factor: 5.250

4.  Pretreatment with delta 1-tetrahydrocannabinol and psychoactive drugs: effects on uptake of biogenic amines and on behavior.

Authors:  M Hershkowitz; H Szechtman
Journal:  Eur J Pharmacol       Date:  1979-11-16       Impact factor: 4.432

5.  Cannabidiol, a non-psychotropic component of cannabis, attenuates vomiting and nausea-like behaviour via indirect agonism of 5-HT(1A) somatodendritic autoreceptors in the dorsal raphe nucleus.

Authors:  E M Rock; D Bolognini; C L Limebeer; M G Cascio; S Anavi-Goffer; P J Fletcher; R Mechoulam; R G Pertwee; L A Parker
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

6.  Antipanic-like effect of serotonin reuptake inhibitors in the elevated T-maze.

Authors:  Selma Conceição Poltronieri; Hélio Zangrossi; Milena de Barros Viana
Journal:  Behav Brain Res       Date:  2003-12-17       Impact factor: 3.332

7.  Facilitation of 5-HT1A-mediated neurotransmission in dorsal periaqueductal grey matter accounts for the panicolytic-like effect of chronic fluoxetine.

Authors:  Janaina M Zanoveli; Roger L H Pobbe; Valquiria C de Bortoli; Milene C Carvalho; Marcus L Brandão; Helio Zangrossi
Journal:  Int J Neuropsychopharmacol       Date:  2009-11-27       Impact factor: 5.176

8.  Evidence for a potential role for TRPV1 receptors in the dorsolateral periaqueductal gray in the attenuation of the anxiolytic effects of cannabinoids.

Authors:  Alline Cristina Campos; Francisco Silveira Guimarães
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2009-09-06       Impact factor: 5.067

9.  Distinct effects of {delta}9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing.

Authors:  Paolo Fusar-Poli; José A Crippa; Sagnik Bhattacharyya; Stefan J Borgwardt; Paul Allen; Rocio Martin-Santos; Marc Seal; Simon A Surguladze; Colin O'Carrol; Zerrin Atakan; Antonio W Zuardi; Philip K McGuire
Journal:  Arch Gen Psychiatry       Date:  2009-01

10.  Antiaversive effects of cannabinoids: is the periaqueductal gray involved?

Authors:  F A Moreira; D C Aguiar; A C Campos; S F Lisboa; A L Terzian; L B Resstel; F S Guimarães
Journal:  Neural Plast       Date:  2008-12-02       Impact factor: 3.599

View more
  21 in total

Review 1.  Cannabidiol regulation of emotion and emotional memory processing: relevance for treating anxiety-related and substance abuse disorders.

Authors:  Jonathan L C Lee; Leandro J Bertoglio; Francisco S Guimarães; Carl W Stevenson
Journal:  Br J Pharmacol       Date:  2017-03-09       Impact factor: 8.739

2.  Novel Pharmacologic Approaches to Treating Cannabis Use Disorder.

Authors:  Rebecca E Balter; Ziva D Cooper; Margaret Haney
Journal:  Curr Addict Rep       Date:  2014-06-01

Review 3.  Are cannabidiol and Δ(9) -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review.

Authors:  John M McPartland; Marnie Duncan; Vincenzo Di Marzo; Roger G Pertwee
Journal:  Br J Pharmacol       Date:  2015-02       Impact factor: 8.739

4.  Neural correlates of interactions between cannabidiol and Δ(9) -tetrahydrocannabinol in mice: implications for medical cannabis.

Authors:  S M Todd; J C Arnold
Journal:  Br J Pharmacol       Date:  2015-11-18       Impact factor: 8.739

5.  The Management of Cancer Symptoms and Treatment-Induced Side Effects With Cannabis or Cannabinoids.

Authors:  Michelle Sexton; Jose M Garcia; Aminah Jatoi; Carey S Clark; Mark S Wallace
Journal:  J Natl Cancer Inst Monogr       Date:  2021-11-28

Review 6.  Defensive and Emotional Behavior Modulation by Serotonin in the Periaqueductal Gray.

Authors:  Priscila Vázquez-León; Abraham Miranda-Páez; Kenji Valencia-Flores; Hugo Sánchez-Castillo
Journal:  Cell Mol Neurobiol       Date:  2022-07-28       Impact factor: 4.231

7.  A double-blind, randomized, placebo-controlled test of the effects of cannabidiol on fear elicited by a 10% carbon dioxide-enriched air breathing challenge.

Authors:  Ellen W Leen-Feldner; Teah-Marie Bynion; Graham M L Eglit; Marcel O Bonn-Miller; L Riley Gournay; Matthew T Feldner
Journal:  Psychopharmacology (Berl)       Date:  2022-10-15       Impact factor: 4.415

Review 8.  The endocannabinoid system as a target for novel anxiolytic drugs.

Authors:  Sachin Patel; Mathew N Hill; Joseph F Cheer; Carsten T Wotjak; Andrew Holmes
Journal:  Neurosci Biobehav Rev       Date:  2017-05       Impact factor: 8.989

Review 9.  Cannabidiol as a Potential Treatment for Anxiety Disorders.

Authors:  Esther M Blessing; Maria M Steenkamp; Jorge Manzanares; Charles R Marmar
Journal:  Neurotherapeutics       Date:  2015-10       Impact factor: 7.620

Review 10.  Overlapping Mechanisms of Stress-Induced Relapse to Opioid Use Disorder and Chronic Pain: Clinical Implications.

Authors:  Udi E Ghitza
Journal:  Front Psychiatry       Date:  2016-05-02       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.